Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The diagnosis of small bowel Crohn’s disease with negative ileocolonoscopic findings has been challenging. Fecal calprotectin (FC) has been used to detect colonic inflammation, but its efficacy for detecting small bowel inflammation is less established. We performed an updated meta-analysis to evaluate the diagnostic accuracy of FC to detect active small bowel inflammation observed during capsule endoscopy. Methods: We conducted a systematic literature search for studies that evaluated the correlation between small bowel inflammation and FC in patients with suspected/established Crohn’s disease. We calculated the pooled sensitivity, specificity, and diagnostic odds ratios (DORs) and constructed hierarchical summary receiver operating characteristic curves for FC cutoffs of 50, 100, and 200 μg/g. Results: Fourteen studies were eligible for the final analysis. The DORs of all FC cutoffs were significant. The highest DOR was observed at 100 μg/g (sensitivity, 0.73; specificity, 0.73; and DOR, 7.89) and was suggested as the optimal diagnostic cutoff. If we analyzed only studies that included patients with suspected Crohn’s disease, the DOR was 8.96. If we analyzed only studies that included patients with a Lewis score ≥135 as a diagnostic criterion for active disease, the DOR was 10.90. Conclusions: FC has significant diagnostic accuracy for detecting small bowel inflammation, and an FC cutoff of 100 μg/g can be used as a tool to screen for small bowel Crohn’s disease.
Abstract
Background/Aims: The diagnosis of small bowel Crohn’s disease with negative ileocolonoscopic findings has been challenging. Fecal calprotectin (FC) has been used to detect colonic inflammation, but its efficacy for detecting small bowel inflammation is less established. We performed an updated meta-analysis to evaluate the diagnostic accuracy of FC to detect active small bowel inflammation observed during capsule endoscopy. Methods: We conducted a systematic literature search for studies that evaluated the correlation between small bowel inflammation and FC in patients with suspected/established Crohn’s disease. We calculated the pooled sensitivity, specificity, and diagnostic odds ratios (DORs) and constructed hierarchical summary receiver operating characteristic curves for FC cutoffs of 50, 100, and 200 μg/g. Results: Fourteen studies were eligible for the final analysis. The DORs of all FC cutoffs were significant. The highest DOR was observed at 100 μg/g (sensitivity, 0.73; specificity, 0.73; and DOR, 7.89) and was suggested as the optimal diagnostic cutoff. If we analyzed only studies that included patients with suspected Crohn’s disease, the DOR was 8.96. If we analyzed only studies that included patients with a Lewis score ≥135 as a diagnostic criterion for active disease, the DOR was 10.90. Conclusions: FC has significant diagnostic accuracy for detecting small bowel inflammation, and an FC cutoff of 100 μg/g can be used as a tool to screen for small bowel Crohn’s disease.
참고문헌 (49)
- Torres J, "Crohn’s disease", Lancet, 389, pp.1741~1755 (2017)
- Abdul-Baki H, "Clinical epidemiology of inflammatory bowel disease in Lebanon", Inflamm Bowel Dis, 13, pp.475~480 (2007)
- Park SH, "A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015", J Crohns Colitis, 13, pp.1410~1417 (2019)
- 백승혁, "Characteristic Phenotypes in Korean Crohn’s Disease Patients Who Underwent Intestinal Surgery for the Treatment", Journal of Korean Medical Science, 28(4), pp.575~579 (2013), 대한의학회
- Gower-Rousseau C, "Epidemiology of inflammatory bowel diseases : new insights from a French population-based registry(EPIMAD)", Dig Liver Dis, 45, pp.89~94 (2013)
- Nuij VJ, "Phenotype of inflammatory bowel disease at diagnosis in the Netherlands : a population-based inception cohort study(the Delta Cohort)", Inflamm Bowel Dis, 19, pp.2215~2222 (2013)
- Sjöberg D, "Incidence and clinical course of Crohn’s disease during the first year : results from the IBD Cohort of the Uppsala Region(ICURE)of Sweden 2005-2009", J Crohns Colitis, 8, pp.215~222 (2014)
- Lapidus A, "Crohn’s disease in Stockholm County during 1990-2001 : an epidemiological update", World J Gastroenterol, 12, pp.75~81 (2006)
- Vind I, "Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005 : a population-based study from the Danish Crohn colitis database", Am J Gastroenterol, 101, pp.1274~1282 (2006)
- Björnsson S, "Inflammatory bowel disease in Iceland, 1990-1994 : a prospective, nationwide, epidemiological study", Eur J Gastroenterol Hepatol, 12, pp.31~38 (2000)
- Van Assche G, "The second European evidence-based consensus on the diagnosis and management of Crohn’s disease : definitions and diagnosis", J Crohns Colitis, 4, pp.7~27 (2010)
- Basso D, "Inflammatory bowel diseases : from pathogenesis to laboratory testing", Clin Chem Lab Med, 52, pp.471~481 (2014)
- Lichtenstein GR, "ACG clinical guideline : management of Crohn’s disease in Adults", Am J Gastroenterol, 113, pp.481~517 (2018)
- Sipponen T, "Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin", Dig Dis, 31, pp.336~344 (2013)
- Menees SB, "A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS", Am J Gastroenterol, 110, pp.444~454 (2015)
- Koulaouzidis A, "Fecal calprotectin : a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy", Scand J Gastroenterol, 46, pp.561~566 (2011)
- Kallel L, "Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon : a prospective study", Eur J Gastroenterol Hepatol, 22, pp.340~345 (2010)
- Egea Valenzuela J, "Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn’s disease", Rev Esp Enferm Dig, 108, pp.394~400 (2016)
- Egea-Valenzuela J, "Fecal calprotectin as a biomarker of inflammatory lesions of the small bowel seen by videocapsule endoscopy", Rev Esp Enferm Dig, 107, pp.211~214 (2015)
- Jensen MD, "Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon", Scand J Gastroenterol, 46, pp.694~700 (2011)
- Kopylov U, "Small bowel capsule endoscopy in the management of established Crohn’s disease : clinical impact, safety, and correlation with inflammatory biomarkers", Inflamm Bowel Dis, 21, pp.93~100 (2015)
- Kopylov U, "Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn’s disease using biomarkers, capsule endoscopy, and imaging", Am J Gastroenterol, 110, pp.1316~1323 (2015)
- Monteiro S, "Fecal calprotectin as a selection tool for small bowel capsule endoscopy in suspected Crohn’s disease", Inflamm Bowel Dis, 24, pp.2033~2038 (2018)
- Olsen PA, "Fecal calprotectin in patients with suspected small bowel disease: a selection tool for small bowel capsule endoscopy?", Scand J Gastroenterol, 50, pp.272~277 (2015)
- Sipponen T, "Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy", Scand J Gastroenterol, 47, pp.778~784 (2012)
- Aggarwal V, "Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn’s disease to assess remission and predict relapse", Gastrointest Endosc, 86, pp.1070~1078 (2017)
- Bar-Gil Shitrit A, "A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn’s disease in patients undergoing capsule endoscopy", Scand J Gastroenterol, 52, pp.328~333 (2017)
- Hale MF, "The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn’s disease", Eur J Gastroenterol Hepatol, 28, pp.1145~1150 (2016)
- Kopylov U, "Detection of Crohn disease in patients with spondyloarthropathy : the SpACE Capsule Study", J Rheumatol, 45, pp.498~505 (2018)
- Yousuf H, "Elevated faecal calprotectin levels are a reliable non-invasive screening tool for small bowel Crohn’s disease in patients undergoing capsule endoscopy", Dig Dis, 36, pp.202~208 (2018)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
- Cotter J, "Validation of the Lewis score for the evaluation of smallbowel Crohn’s disease activity", Endoscopy, 47, pp.330~335 (2015)
- Fireman Z, "Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy", Gut, 52, pp.390~392 (2003)
- Reitsma JB, "Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews", J Clin Epidemiol, 58, pp.982~990 (2005)
- Balduzzi S, "How to perform a metaanalysis with R : a practical tutorial", Evid Based Ment Health, 22, pp.153~160 (2019)
- "Meta-analysis of diagnostic accuracy with mada" (2015)[URL]
- Kopylov U, "Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn’s disease", Therap Adv Gastroenterol, 9, pp.655~663 (2016)
- 최미영, "Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn’s Disease: A Meta-Analysis", Gut and Liver, 11(1), pp.62~72 (2017), 거트앤리버 소화기연관학회협의회
- Ida Hilmi, "Capsule endoscopy in inflammatory bowel disease: when and how", Intestinal research, 18(3), pp.265~274 (2020), 대한장연구학회[DOI]
- Annese V, "European evidence based consensus for endoscopy in inflammatory bowel disease", J Crohns Colitis, 7, pp.982~1018 (2013)
- Lobatón T, "A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease", J Crohns Colitis, 7, pp.e641~ (2013)
- Mosli MH, "C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients : a systematic review and meta-analysis", Am J Gastroenterol, 110, pp.802~819 (2015)
- Sood R, "Systematic review with meta-analysis : the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and", or psychological markers, 2015, pp.42, 491~503
- Turner D, "Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis : a prospective multicentre comparison of predicting outcomes and monitoring response", Gut, 59, pp.1207~1212 (2010)
- Ebby George Simon, "Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review", Intestinal research, 17(2), pp.160~170 (2019), 대한장연구학회[DOI]
- Tham YS, "Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease : systematic review and meta-analysis", Therap Adv Gastroenterol, 11, pp.1756284818785571~ (2018)
- Stawczyk-Eder K, "Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study", Arch Med Sci, 11, pp.353~361 (2015)
- Zittan E, "Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn’s disease activity", JGH Open, 2, pp.201~206 (2018)
- Kopylov U, "Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 28, pp.1137~1144 (2016)